Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/17701
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tosheska Trajkovska, Katerina | en_US |
dc.contributor.author | Kostovska, Irena | en_US |
dc.contributor.author | Bosilkova, Gordana | en_US |
dc.date.accessioned | 2022-05-19T12:22:14Z | - |
dc.date.available | 2022-05-19T12:22:14Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.12188/17701 | - |
dc.description.abstract | Background. It is well known that a standard lipid profile measures total cholesterol, triglycerides, and HDL cholesterol (HDL-c), while LDL cholesterol is estimated. Subtracting HDL-c from total cholesterol, we can measure the amount of cholesterol carried by all lipoproteins except HDL. This simple math will give the amount of non-HDL cholesterol (non-HDL-c) within all atherogenic lipoproteins. However, although it is so easy, biochemical laboratories rarely report the value of non-HDL-c. Aim of the study. The aim of our study is to highlight the results of several studies that clearly establish the clinical use of non–HDL cholesterol as a common predictor of blood lipid patterns associated with increased risk of heart disease. Material. Recent literary evidence and clinical studies. Results. The most important document regarding non-HDL-c was delivered by the National Cholesterol Education Program Adult Treatment Panel III, where non–HDL-c was highlighted as a key secondary goal of therapy in lipid treatment and lipoprotein management. Other studies suggest that non-HDL-c shows a better correlation with small dense LDL particles than do other lipid parameters, including LDL-c. The treatment goal for non-HDL-c is usually 30 mg/dL above the LDL-c treatment target. Conclusion. Knowing that non–HDL-c is superior to LDL-c for the prediction of cardiovascular events, it is very important for each clinical chemistry laboratory to report non–HDL-c as a part of routine lipid status, with no added expense. Doctors could use it for optimal prevention of atherosclerosis and cardiovascular disease. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BioMed Central Ltd. | en_US |
dc.relation.ispartof | EPMA Journal | en_US |
dc.subject | non HDL cholesterol | en_US |
dc.subject | blood lipids | en_US |
dc.subject | predictor | en_US |
dc.subject | heart disease | en_US |
dc.subject | laboratory report | en_US |
dc.title | The importance of routinely reporting non-HDL cholesterol by the clinical laboratory | en_US |
dc.type | Proceeding article | en_US |
dc.relation.conference | EPMA World Congress 2017, Malta | en_US |
dc.identifier.doi | 10.1007/s13167-017-0108-4 | - |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
crisitem.author.dept | Faculty of Medicine | - |
crisitem.author.dept | Faculty of Medicine | - |
crisitem.author.dept | Faculty of Medicine | - |
Appears in Collections: | Faculty of Medicine: Conference papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2017_Article_EPMAWorldCongress (1).pdf | 8.94 MB | Adobe PDF | View/Open |
Page view(s)
51
checked on May 9, 2024
Download(s)
6
checked on May 9, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.